Stocks and Investing
Stocks and Investing
Thu, March 16, 2017
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Downgraded (BIIB) to Hold and Decreased Target to $305 on, Mar 16th, 2017
Matthew Harrison of Morgan Stanley, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $369 to $305 on, Mar 16th, 2017.
Matthew has made no other calls on BIIB in the last 4 months.
There are 2 other peers that have a rating on BIIB. Out of the 2 peers that are also analyzing BIIB, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alethia Young of "Cantor Fitzgerald" Initiated at Hold and Held Target at $293 on, Friday, December 16th, 2016
This is the rating of the analyst that currently disagrees with Matthew
- Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy on, Wednesday, February 8th, 2017
Contributing Sources